PROSTATE CANCER

Bicalutamide (Casodex), an anti - androgen-corticosteroids, which can be used as the treatment of advanced prostate cancer assistant drug, may also in the treatment of early prostate cancer play an important role. According to Canada "Medical Post" (2001,37:27), the study of 23 countries into the 8113 cases (38 ~ 93 years) and the limitations of locally advanced prostate cancer were three prospective, double-blind, randomized, placebo-controlled study. 4,052 cases received bicalutamide 150mg per Yue treatment; 4,061 cases were receiving placebo treatment two years and acceptable standard resection or radiotherapy. Right to be diagnosed in patients before diagnosis only radiotherapy. Follow-up medication group 4,052 cases, 4,061 cases placebo group. Results cancer medication group progress risk reduction 47%, the survival rate increased by about 20%. A very small number of patients (including the elderly) because of adverse reactions stopping medication. In each hot flashes and impotence 9% (placebo group were 5.2% and 6.1%).